米氮平与帕罗西汀治疗抑郁症的疗效和安全性

Efficacy and safety of mirtazapine and paroxetine in the treatment of depression

目的:分析米氮平与帕罗西汀治疗抑郁症的临床疗效及安全性。方法:2018年2月-2020年2月收治抑郁症患者84例,随机分为两组,各42例。对照组给予帕罗西汀治疗,试验组给予米氮平+帕罗西汀治疗,比较两组患者HAMA评分、HAMD评分、WMS-RC评分、血清炎性因子水平及不良反应发生率。结果:试验组治疗后HAMA评分、HAMD评分、血清TNF-α及IL-6水平均低于对照组,WMS-RC评分高于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:米氮平+帕罗西汀可有效减轻抑郁症患者焦虑、抑郁症状及炎症反应,提高智力,且不良反应较少。

Objective:To analyze the clinical efficacy and safety of mirtazapine and paroxetine in the treatment of depression.Methods:From February 2018 to February 2020,84 patients with depression were selected and randomly divided into two groups with 42 patients in each group.The control group was treated with paroxetine.The experimental group was treated with mirtazapine and paroxetine.HAMA score,HAMD score,WMS-RC score,serum inflammatory factor level and the incidence of adverse reactions between the two groups were compared.Results:After treatment,HAMA score,HAMD score,serum TNF-αand IL-6 levels in the experimental group were lower than the control group,and WMS-RC score was higher than the control group,with the differences were statistically significant(P<0.05).The incidence of adverse reactions between the two groups was compared,with the difference was not statistically significant(P>0.05).Conclusion:Mirtazapine and Paroxetine can effectively relieve anxiety,depression symptoms and inflammatory responses,and improve intelligence in patients with depression,with less adverse reactions.